Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Alan Greenspan, architect of the modern American economy, dies aged 100

Published

on

Alan Greenspan, architect of the modern American economy, dies aged 100

As chairman of the Federal Reserve, Alan Greenspan became the world’s most high-profile banker.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Apogee Therapeutics Shares Surge 46 Percent to 132.70 on Positive Clinical Developments

Published

on

Apogee Therapeutics Shares Surge 46 Percent to 132.70 on Positive

NEW YORK — Apogee Therapeutics Inc. shares experienced dramatic gains Monday, rising more than 46 percent to $132.70 in morning trading. The biotechnology company’s stock movement reflected strong investor reaction to advancements in its clinical pipeline and potential for significant therapeutic breakthroughs.

Trading volume for Apogee Therapeutics surged substantially above average levels, indicating broad participation from institutional and retail investors. The percentage increase placed the stock among the day’s top performers on major exchanges, generating considerable market attention.

Biotechnology companies frequently see sharp price movements following clinical trial updates or regulatory milestones. Apogee Therapeutics, focused on developing innovative antibody therapies, has positioned itself in competitive areas of immunology and inflammatory diseases. Monday’s surge suggested positive interpretations of recent company progress.

The session’s gains occurred within a broader healthcare sector showing selective strength. While major indices demonstrated modest movements, individual biotechnology names responded to company-specific catalysts. Apogee Therapeutics stood out due to the magnitude of its advance and trading interest.

Advertisement

Analysts following the company have highlighted its novel approaches to treating complex conditions. Research efforts target specific pathways that could offer improved efficacy and safety profiles compared to existing treatments. Positive developments in clinical programs often trigger substantial market responses in the biotechnology sector.

Apogee Therapeutics operates within a dynamic environment where scientific innovation drives value creation. The sector features high research and development costs alongside substantial commercial potential for successful products. Monday’s trading reflected investor optimism regarding the company’s therapeutic candidates and development strategy.

Trading patterns for Apogee Therapeutics have shown volatility typical of clinical-stage biotechnology firms. Share prices often react sharply to news regarding trial results, intellectual property and strategic partnerships. The current advance suggests favorable assessments of recent activities and future prospects.

Broader healthcare trends provided supportive context for the stock’s performance. Increased focus on precision medicine and targeted therapies has benefited companies pursuing innovative treatment approaches. Apogee Therapeutics’ positioning within this landscape may have contributed to investor enthusiasm.

Advertisement

Market observers noted elevated options activity around Apogee Therapeutics, indicating speculative interest in near-term movements. Such activity frequently accompanies significant news or anticipation of upcoming catalysts. The stock’s liquidity supported active trading throughout the morning session.

The biotechnology industry’s competitive nature requires continuous scientific advancement and strategic execution. Apogee Therapeutics’ efforts to advance its pipeline demonstrate commitment to addressing unmet medical needs. Success in clinical development could substantially impact the company’s market position and valuation.

Investor sentiment toward biotechnology has fluctuated based on regulatory environments and commercial considerations. Monday’s gains for Apogee Therapeutics suggested positive views regarding its specific programs and overall development approach.

Company leadership has emphasized rigorous scientific methods and patient-centered development. Such priorities align with industry standards while addressing stakeholder expectations. Strategic decisions about clinical trials and potential collaborations influence market perceptions.

Advertisement

The session’s performance added Apogee Therapeutics to lists of notable market movers. Percentage gains of this magnitude often generate media coverage and increased analyst attention. Investors and observers will likely monitor the stock closely for follow-through or consolidation patterns.

Biotechnology investing requires understanding scientific fundamentals alongside financial metrics. Apogee Therapeutics’ pipeline progress represents key value drivers while cash position and operational efficiency affect near-term stability. Balanced assessment involves multiple considerations.

Market dynamics for biotechnology companies often feature rapid price movements based on news flow. Apogee Therapeutics’ surge exemplified this characteristic while highlighting the sector’s potential for substantial returns. Risk management remains essential given development uncertainties.

Looking ahead, Apogee Therapeutics faces typical biotechnology milestones that could influence future performance. Clinical trial results, regulatory interactions and potential business development activities represent significant potential catalysts. Investors will evaluate these against competitive landscapes and commercial prospects.

Advertisement

The broader market environment continues evolving with attention to economic indicators and policy developments. Biotechnology companies navigate these conditions while pursuing scientific objectives. Apogee Therapeutics’ recent performance suggests resilience amid varying external factors.

Trading activity showed strong momentum for Apogee Therapeutics shares. The 46.82 percent increase reflected significant buying interest and positive sentiment. Market participants will assess whether this momentum sustains or experiences typical profit-taking.

Overall, Apogee Therapeutics’ stock surge highlighted the biotechnology sector’s capacity for dramatic movements. The company’s developments attracted substantial investor attention while contributing to market narratives about innovation and therapeutic potential. Continued monitoring of fundamental progress will remain important for long-term assessments.

Advertisement
Continue Reading

Business

Jaguar Land Rover could face battery supply wait after Agratas factory changes

Published

on

Business Live

Tata-owned Agratas is building a huge plant in Somerset but changed its main contractor last week

Aerial view of the Agratas gigafactory within the Gravity enterprise zone. CREDIT: Agratas. Free to use for all BBC wire partners.

Aerial view of the Agratas gigafactory within the Gravity enterprise zone(Image: Local Democracy Reporting Service)

Car giant Jaguar Land Rover could face delays receiving its first deliveries of electric car batteries from a government-backed factory in Somerset if the plant’s opening date is pushed back.

Battery maker Agratas confirmed last week it had “parted ways” with its main builder, Sir Robert McAlpine (SRM), and replaced it with Tonroe Group – a privately owned business based in Buckinghamshire – instead.

Agratas, which is owned by Indian conglomerate Tata, is currently building a £5.2bn plant on a site near Bridgwater. It will supply electric batteries to JLR as well as Tata Motors once operational.

When Tata first announced plans for its UK plant in 2023, it was targeting a 2026 launch. On Monday, the company insisted the start date for production was still expected to be late 2027 amid reports it could be pushed back to 2028.

Advertisement

It also refused to reveal the final estimated price-tag for the project after the Guardian reported at the weekend that it could exceed its original £800m construction budget by at least £500m.

A spokesperson for Agratas said: “As the project has progressed, we have determined that a different construction delivery model is needed to support the next phase of our development.

“Following a review of the project’s requirements, we have decided to transition to a new construction partner. We thank our existing construction partner for their support to date.

“This change reflects the evolving needs of the project, positioning us to deliver the next phase with the capability and focus required to meet our objectives safely, efficiently and on schedule.”

Advertisement

In April, the government promised some £380m in subsidies for the Agratas factory, which is based at the Gravity Smart Campus – a 616-acre enterprise zone in Somerset aimed at cleantech businesses. The project is widely regarded as key for Britain’s automotive sector moving towards electrification – and away from fossil fuels.

The plant is expected to generate up to 4,200 jobs once all phases are fully operational, while also unlocking 300 local apprenticeships.

But delays to the start of factory production could prove problematic for JLR, which will depend on the plant for batteries for its vehicles, including the electric Range Rover.

JLR declined to comment on Monday when contacted by Business Live.

Advertisement

It comes just days after JLR announced plans to focus on wealthy North American buyers as it bids for ‘double digit’ revenue growth and tweaks its electric vehicle plans.

The West Midlands based group, which also has a large factory at Halewood in Merseyside, has accelerated its push into the electric vehicle market in recent years, but its chief executive PB Balaji has said there is “no way” it would phase out petrol vehicles entirely as they are still in demand particularly in the US and the Middle East.

Continue Reading

Business

Lam Research: A Strong Buy Built On Memory, Packaging And AI Complexity (NASDAQ:LRCX)

Published

on

Lam Research: A Strong Buy Built On Memory, Packaging And AI Complexity (NASDAQ:LRCX)

This article was written by

My background is in Financial Engineering and I have long since been interested in analyzing strong solid companies with a rare financial Profile. My primary area of specialization is in quantamental analysis, where I use a combination of data driven models and fundamental research. My approach is centered on a structured process that combines top-down screening with bottom-up company specific analysis .I write on to share ideas with a wider audience and also learn more about companies and other analysts. My goal is to make unique ideas & research accessible to retail and professional investors alike, while maintaining analytical depth and a clear investment thesis.Associated with another author Kennedy Njagi

Analyst’s Disclosure: I/we have a beneficial long position in the shares of LRCX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

The importance of the co-operatives and mutuals to the Welsh economy

Published

on

Business Live

Chief executive of Cwmpas Bethan Webber says this year’s co-operatives fortnight is a moment to celebrate the businesses already showing what is possible

Chief executive of Cwmpas Bethan Webber

.People’s experience of the economy is complex and often disconnected from headline growth. Economies can expand while communities remain fragile. Investment may flow in, but little wealth stays local.

Jobs can be created without giving workers real security, a meaningful voice or a genuine stake in success.

That is why during this year’s co-operatives fortnight(which runs to July 3rd) , we are focusing on a different economic vision for Wales: one that has community wealth building at the heart.

It asks a simple but powerful question: how can we support all communities and places to create wealth, and ensure that more of it stays in that place, circulates through local communities, and benefits the people who live and work there?

Advertisement

It is not a slogan, and it is not a rejection of wider investment. Foreign direct investment will continue to matter and be a catalyst for growth. But if we want a more resilient, productive and inclusive economy, we also need to pay closer attention to local enterprise, democratic ownership and fair work.

In other words, community wealth building is about redesigning the architecture of the Welsh economy. Who owns businesses? Where do profits go? How are public contracts used? Are local firms supported to grow? Do workers share in success? Are communities simply consulted, or are they active participants?

These questions are at the heart of the co-operative movement but are relevant beyond it too.

They matter to entrepreneurs who want to build Welsh businesses across the board. They matter to public bodies who want more value from spending. They matter to investors who understand that resilient local economies are good places to do business. They matter to workers, families and communities who want growth to feel real in their everyday lives.

Advertisement

Wales is a small nation with strong communities, a proud tradition of co-operation, and enormous economic potential. But we also face long-standing challenges, not least stubborn poverty, low productivity, regional inequality, and a loss of wealth from local economies.

Community wealth building gives us a practical way of responding to those challenges. It asks us to move from an economic development model that too heavily relies on attracting activity from outside, towards one that also grows capacity from within.

That means supporting Welsh entrepreneurs. It means helping locally-rooted businesses scale. It means using procurement to strengthen Welsh supply chains. And crucially for us at Cwmpas, it means backing co-operative and social business models that also keep ownership and decision-making closer to the people and places where economic value is created.

Co-operatives, employee-owned businesses and social enterprises are central to this because they change the relationship between business success and community benefit.

Advertisement

The co-operative and mutual Economy 2025 report identifies 519 co-operatives in Wales, with around £500m in income. Wales leads the UK for co-operative new-starts per person. In the wider social economy, Wales now has more than 3,100 social businesses, with a turnover of up to £5.7bn each year and employing up to 68,000 people – with our mapping data showing that 84% pay the Real Living Wage to all staff.

A powerful example of what success looks like is Dulas, a worker-owned co-operative based in Machynlleth. Dulas exports solar-powered vaccine refrigerators to more than 80 countries, helping protect life-saving vaccines in some of the hardest-to-reach communities in the world. In 2024, it was named SME Exporter of the Year at the Wales Business Awards.

This shows what co-operative success can look like – locally rooted and globally relevant. It proves that Welsh-owned enterprises can innovate, export, create skilled jobs and make a huge impact without losing their connection to place.

Since 2020, Wales has seen the number of employee-owned businesses grow from 34 to more than 100. That growth shows what can happen when a clear ambition is matched with specialist support and market development. Instead of successful Welsh firms being sold to distant owners when the owner is reaching retirement, it keeps them rooted and anchored in Wales. It protects jobs, shares wealth, and supports passionate entrepreneurs to leave a legacy in the places that mean so much to them.

Advertisement

We can already see the benefits in businesses such as BIC Innovation, which has seen its employee numbers more than triple since becoming employee-owned.

We have a strong platform for growth, but Wales has not yet fully realised its co-operative potential. A community wealth building approach can make these questions central to economic policy.

As part of a new and integrated approach, it would complement other economic development, improving the Welsh economy from the bottom-up, in a way that strengthens local ownership, builds Welsh supply chains, improves job quality and gives communities a greater stake. That is the rebalancing Wales needs.

Cwmpas believes this is now one of the most important economic opportunities facing Wales. We need to move from celebrating individual examples to building the infrastructure that allows many more to emerge, consistently and across the country.

Advertisement

That means specialist business support and market development. It means better access to finance, stronger links between public procurement and local enterprise, and a clearer role for co-operative and employee-owned models in national economic strategy.

This year’s c-operatives fortnight is a moment to celebrate the businesses already showing what is possible. But it should also be a moment to think bigger. If we want growth that lasts, wealth that stays, and communities that have real power over their economic future, community wealth building must become central to how Wales thinks about prosperity.

The task now is to turn that principle into practice.

Advertisement
Continue Reading

Business

Record defence export deal puts Australia on the radar

Published

on

Record defence export deal puts Australia on the radar

Australia has struck its largest defence export deal under a $2.5 billion agreement to provide Canada with world-leading radar technology.

Continue Reading

Business

UPS to invest $48 million in cold facilities amid GLP-1 boom

Published

on

UPS to invest $48 million in cold facilities amid GLP-1 boom

United Parcel Service (UPS) trucks are parked at a UPS drop yard on Oct. 28, 2025 in Vernon, California.

Mario Tama | Getty Images

United Parcel Service is investing $48 million in 27 temperature‑controlled facilities as the industry sees a boom in healthcare logistics, CNBC has learned exclusively.

Advertisement

The facilities, located across the Americas, Europe and Asia, are optimized for moving around shipments that need to be kept at certain temperatures. The company said the investment will help it stay ahead of a boom in medicines and pharmaceuticals — like some GLP-1s — that have to be kept at certain temperatures by improving speed and end-to-end chain of custody.

“Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,” said Kate Gutmann, UPS’ president of international, healthcare and supply chain solutions. “This effort – and all of our work in healthcare logistics – extends from a deep understanding that we’re doing more than moving packages.”

The demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate through 2033 and reach a market value of roughly $39.1 billion, according to Growth Market Reports. Many new medicines are required to be stored at specific temperatures to maintain efficacy, UPS said, making healthcare logistics more crucial than before.

According to the World Health Organization, up to 50% of global vaccines are wasted every year, with a significant portion of that coming from cold-chain storage issues.

Advertisement

“These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes,” UPS Healthcare President John Bolla said in a statement.

UPS’ move comes as the industry overall has seen growing investments in the space, especially with the meteoric rise of GLP-1 drugs. Medicines like Novo Nordisk‘s Wegovy and Ozempic require strict refrigeration and temperature control during transit. A November KFF poll found that 1 in 8 Americans are taking GLP-1s.

UPS CEO Carol Tomé said on the company’s first-quarter earnings call in April that healthcare remains one of the company’s top priorities and biggest areas of growth.

“Our global healthcare portfolio has gained market share every year since 2021,” she said on the call. “And in the first quarter of this year, we generated our first $3 billion healthcare revenue quarter ever, with all three of our segments delivering year-over-year revenue growth.”

Advertisement

Tomé added that UPS is committed to continuing to “lean into that space in a meaningful way.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)

Published

on

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)

This article was written by

I would describe myself as a barbell investor focused on two ends of the risk spectrum: relatively safe, income-generating investments on one side, and high-risk, high upside opportunities—primarily binary healthcare and biotech bets—on the other. Professionally, I work as an R&D researcher in the pharmaceutical industry. Combined with my background in economics and self-training in finance, this provides me with unique perspective when evaluating biotech companies. My research spans multiple dimensions of the sector, including platform technologies, IP and freedom-to-operate considerations, mechanistic feasibility, competitive landscapes, binary clinical trial readouts and corporate financials. As an individual investor, I place significant emphasis on valuation, risk management and capital allocation. On the income-investing side of the portfolio, I actively follow dividend paying stock picks, including preferred shares, REITs, BDCs and option-based income ETFs. The objective is to build a durable stream of cash flow that can support moonshot bets on the other side of the barbell. Through my writing on Seeking Alpha, I aim to share independent, research-driven investment ideas from both ends of this barbell approach. My goal is to combine scientific insight, fundamental analysis and risk management to encourage disciplined trading and develop well-grounded investment thesis.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SMMT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Form 4 The York Water Company For: 22 June

Published

on


Form 4 The York Water Company For: 22 June

Continue Reading

Business

The long tail of Trump’s trade agenda

Published

on

The long tail of Trump’s trade agenda

Industry experts say the latest proposals are designed to outlast court challenges, political cycles and administrations. 

Continue Reading

Business

Schwebel Baking set to shut down

Published

on

Schwebel Baking set to shut down

Longtime commercial baker to wind down operations over the summer.

Continue Reading

Trending

Copyright © 2025